Madison, WINCT07281924Now EnrollingIRB Ready

Metastatic Melanoma Clinical Trial in Madison, WI

Access cutting-edge metastatic melanoma treatment through this phase 1/2 clinical trial at a research site in Madison. Study-provided care at no cost to qualified participants.

Sponsored by University of Wisconsin, Madison

Quick Self-Assessment

See if you qualify for this Madison location

Preparing your pre-screening questions…

Expert Care in Madison

Access metastatic melanoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic melanoma treatment provided free

Apply for This Madison Location

Check if you qualify for this metastatic melanoma clinical trial in Madison, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Madison

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Madison site if eligible
  4. 4Begin participation

About This Metastatic Melanoma Study in Madison

This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients with liver metastasis treated with combination immune checkpoint inhibitor therapy.

Sponsor: University of Wisconsin, Madison

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed metastatic melanoma with liver metastasis (LM). Liver biopsy positive for presence of melanoma metastases is required.
Systemic treatment naïve in the unresectable/metastatic setting - prior adjuvant anti-programmed cell death-1 (anti-PD-1) and BRAF/MEK targeted therapy is allowed but must be greater than 6 months from the last treatment.
Evaluable/measurable disease according to RECIST v1.1.
Demonstrate adequate organ function; all screening labs to be obtained within 28 days prior to registration.
Patients must weigh greater than or equal to 35 kilograms (due to possible size limitations with respect to percutaneous catheterization of the femoral artery and vein using the Delcath Hepatic Delivery System).

Exclusion Criteria

Prior treatment with HEPZATO KIT™ or nivolumab and relatlimab (Opdualag™)
Radiotherapy is permitted within 30 days prior to C1D1 as long as radiation is given with palliative intent and towards a non-target lesion.
History of hypersensitivity or treatment discontinuation due to grade 3+ immune-related adverse events (irAEs) from prior anti-PD-(L)1 therapy. Patients who are able to successfully resume immune checkpoint therapy without recurrence of grade 3 irAEs are eligible to participate.
Symptomatic or uncontrolled brain metastases, leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation.
Prednisone use greater than or equal to 10 mg/d or equivalent
Organ transplant recipients

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Madison?

Yes, this clinical trial (NCT07281924) has an active research site in Madison, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Melanoma Treatment Options in Madison, WI

If you're searching for metastatic melanoma treatment options in Madison, WI, this clinical trial (NCT07281924) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Madison research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced metastatic melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic melanoma clinical trials near you to find additional studies recruiting in your area.

More Melanoma Trials in Madison, WI

See all melanoma clinical trials recruiting in Madison — not just this study.

Browse Melanoma Trials in Madison →

Browse More Trials by Condition

Melanoma TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Madison?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Madison, WI